Q 1802
Alternative Names: Q-1802Latest Information Update: 03 Aug 2023
At a glance
- Originator QureBio
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Gastric cancer
- Phase I Solid tumours
Most Recent Events
- 21 Jun 2023 Phase-I/II clinical trials in Gastric cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, First-line therapy) in China (IV) (NCT05964543)
- 03 Jun 2022 Safety, efficacy and pharmacokinetics data from a phase Ia/Ib trial in Solid tumours presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
- 31 May 2022 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (Parenteral) (NCT04856150)